ArticleDrug design, development and therapy2015
Solid lipid nanoparticles loaded with iron to overcome barriers for treatment of iron deficiency anemia.
Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 68 citations in OpenAlex.
- Advances in Iron Deficiency Anaemia Management: Exploring Novel Drug Delivery Systems and Future Perspectives.Current drug delivery · 2025Review
- Nanoscale coordination polymer Fe-DMY downregulating Poldip2-Nox4-HJournal of pharmaceutical analysis · 2023Article
- Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions.Pharmaceutics · 2023Review
- Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases.Frontiers in genome editing · 2022Review
- Iron, Copper, and Zinc Homeostasis: Physiology, Physiopathology, and Nanomediated Applications.Nanomaterials (Basel, Switzerland) · 2021Review
- Nanotechnology: A novel tool to enhance the bioavailability of micronutrients.Food science & nutrition · 2021Review
- Stability enhancement of lycopene inFood science & nutrition · 2021Article
- Intestinal and hepatic effects of iron oxide nanoparticles.Archives of toxicology · 2021Article
- Iron Deficiency Anemia in Children Residing in High and Low-Income Countries: Risk Factors, Prevention, Diagnosis and Therapy.Mediterranean journal of hematology and infectious diseases · 2020Review
- Nanoparticles for hematologic diseases detection and treatment.Hematology & medical oncology · 2019Article
- Potential of Nanomaterial Applications in Dietary Supplements and Foods for Special Medical Purposes.Nanomaterials (Basel, Switzerland) · 2019Review
- Modern iron replacement therapy: clinical and pathophysiological insights.International journal of hematology · 2018Review
- Iron oxide nanoparticles can cross plasma membranes.Scientific reports · 2017Article
- The Improvement of Skin Whitening of Phenylethyl Resorcinol by Nanostructured Lipid Carriers.Nanomaterials (Basel, Switzerland) · 2017Article
- Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers.Journal of food and drug analysis · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the World Health Organization, 46% of the world's children suffer from anemia, which is usually treated with iron supplements such as ferrous sulfate. The aim of this study was to prepare iron as solid lipid nanoparticles, in order to find an innovative way for alleviating the disadvantages associated with commercially available tablets. These limitations include adverse effects on the digestive system resulting in constipation and blood in the stool. The second drawback is the high variability in the absorption of iron and thus in its bioavailability. Iron solid lipid nanoparticles (Fe-SLNs) were prepared by hot homogenization/ultrasonication. Solubility of ferrous sulfate in different solid lipids was measured, and effects of process variables such as the surfactant type and concentration, homogenization and ultrasonication times, and charge-inducing agent on the particle size, zeta potential, and encapsulation efficiency were determined. Furthermore, in vitro drug release and in vivo pharmacokinetics were studied in rabbits. Results indicated that Fe-SLNs consisted of 3% Compritol 888 ATO, 1% Lecithin, 3% Poloxamer 188, and 0.2% dicetylphosphate, with an average particle size of 25 nm with 92.3% entrapment efficiency. In vivo pharmacokinetic study revealed more than fourfold enhanced bioavailability. In conclusion, Fe-SLNs could be a promising carrier for iron with enhanced oral bioavailability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.